Mark Stejbach, Director at Flexion Therapeutics Inc (FLXN), bought 1,580 shares at $17.02 ($27K) on 2017-06-16, disclosed to the SEC on 2017-06-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| ALKS | SELL | 2018-02-21 | $767K | — | Filing → |
| ALKS | SELL | 2017-06-08 | $603K | — | Filing → |
| ALKS | SELL | 2017-01-10 | $33K | — | Filing → |